PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the multiple daily injection therapy and continuous subcutaneous insulin infusion markets.
Presenters will be available to discuss the posters at the following times:
"Human Hyaluronidase Plus Rapid Analog Insulin (RAI) Improves Postprandial Glycemic Control in Type 2 Diabetes (T2DM) Compared to Insulin Lispro Alone," Saturday, June 9 from 12:30 – 1:30 PM EDT during an audio guided tour and on Sunday, June 10 from 12:00 - 2:00 PM EDT.
"Human Hyaluronidase (rHuPH20) Provides Consistent Ultrafast Insulin Absorption and Action Over Three Days of Continuous Subcutaneous Infusion," Sunday, June 10 from 12:00 - 2:00 PM EDT.
"With diabetes reaching epidemic proportions globally, the need for improved therapies that can help people better manage the all too common rollercoaster ride of glucose swings is critical," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "Pairing Halozyme's lead enzyme, rHuPH20, with mealtime analog insulins accelerates the absorption and action of prandial insulins, helps moderate glucose fluctuations and enables patients to achieve tighter control of this chronic disease."
882-P: Human Hyal